PTPA and breast carcinoma: Therefore, these results reinforce our clinical results regarding to the impact of the CPscore with doxorubicin resistance in breast cancer, and the potential therapeutic value of FTY720-induced PP2A activation in combination with doxorubicin in breast cancer.